 The metalloproteinases that release TNF-alpha, TNF-II, L-selectin, IL-1-RII and IL-6 are for example not inhibited by Rebimastat.In phase I of clinical trials, there was no sign of dose-dependent joint toxicity and a disease stabilization.Arthralgia was noted in phase II early breast cancer trials, which was connected to MMP inhibitor toxicity.